Effectiveness of a 5-Day External Stenting Protocol on Urological Complications After Renal Transplantation by Minnee, Robert C. et al.
Effectiveness of a 5-Day External Stenting Protocol on Urological
Complications After Renal Transplantation
Robert C. Minnee Æ Frederike J. Bemelman Æ
Pilar P. Laguna Pes Æ Ineke J. M. ten Berge Æ
Dink A. Legemate Æ Mirza M. Idu
Published online: 23 September 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Background Ureteral stents are successful in reducing
urological complications after renal transplantation. How-
ever, the optimal duration and method of stenting have not
yet been clariﬁed. The objective of the present study was to
investigate the frequency of urological complications when
a 5-day external stented ureterocystostomy protocol was
followed.
Methods A single-center nonrandomized analysis of 392
kidney transplantations between June 2003 and June 2007
was conducted. From July 2005 all 196 renal transplant
recipients received a 5-day external stented ureterocystos-
tomy. A urological complication was deﬁned as any cause
leading to the placement of a percutaneous nephrostomy
catheter and/or surgical revision of the ureterocystostomy.
Results In the non-stented group, 21 of the 196 patients
(10.7%) developed a urological complication compared to
13 patients (6.6%) in the stented group (p = 0.151). In the
stented group, 2 of the 66 recipients of a living donor
transplant (3.0%) developed a urological complication
comparedto8ofthe59recipients(13.6%)inthenon-stented
group (P = 0.030). Eleven of 130 recipients of a deceased
donor transplant (8.5%) in the stented group developed a
urological complication, compared to 13 of the 137 recipi-
ents (9.5%) in the non-stented group (P = 0.769). The sur-
gical revision rate of the stented and the non-stented group
was 5/13 39% and 6/21 29%, respectively.
Conclusions A 5-day routine external stent protocol is
efﬁcacious in living donor renal transplantation in pre-
venting early postoperative ureter obstruction, but this
stenting period seems inadequate for deceased donor renal
transplantation.
Introduction
Urological complications remain an important source of
morbidity and occasionally mortality, after renal trans-
plantation. The two major urological complications after
renal transplantation are urinary leakage and obstruction,
mostly located at the ureterovesical junction or in the distal
transplant ureter.
Two meta-analyses have demonstrated that on compar-
ison with a non-stented ureterocystostomy, a stented ure-
terocystostomy leads to a signiﬁcantly lower urological
complication rate (odds ratio 0.24, 95% conﬁdence interval
[CI] 0.07–0.77; P = 0.02) [1, 2]. This ﬁnding has been
conﬁrmed by two recent studies, one of which showed that
stenting was more cost-effective. Accordingly, we changed
our surgical technique from non-stented to stented ureter-
ocystostomy [3, 4].
However, using a routine stenting protocol, the number
needed to treat (NNT) to prevent one urological compli-
cation is high, ranging from 10 to 30 [2]. In addition, the
optimal duration of stenting and method of stenting have
yet to be determined.
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of a short (5-day) external stented ureterocystostomy pro-
tocol on the occurrence of urological complications.
Patients and methods
All 392 consecutive patients who underwent renal trans-
plantation between June 2003 and June 2007 at the Aca-
demic Medical Center, Amsterdam, were included in the
study. From July 2005 all 196 renal transplant recipients
received a 5-day external stented ureterocystostomy. All
procedures were single renal transplants performed through
an extraperitoneal approach in the iliac fossa. The renal vein
was anastomosed to the external iliac vein, and the renal
artery was anastomosed to the external iliac artery. The
method used to establish urinary continuity was either the
extravesical ureterocystostomy (Lich–Gregoir method) or
the intravesical ureterocystostomy (Politano–Leadbetter
method), according to the personal preference of the sur-
geon. The ureteroneocystostomy was stented with an
externally draining 8 French (Fr) catheter for 5 days. The
stent was introduced into the bladder through a direct
suprapubic bladder puncture and positioned in the trans-
plant renal pelvis. The stent drained externally and was
sutured to the bladder mucosa and to the skin. Postopera-
tively all patients had an indwelling bladder catheter. The
operation day was counted as day 0. The stent was routinely
removed on the ﬁfth postoperative day.
The bladder catheter was removed in all patients on day 7
after urinary leakage had been excluded by cystography on
the same day. All patients were followed at our center for at
least 1 year after successful transplantation. After 1 year,
patients were transferred to their referral center. Standard
immunosuppressionconsistedofprednisolone,acalcineurin
inhibitor, mycophenolate mofetil, and prophylactic anti-
CD25 monoclonal antibody (basiliximab). Initial episodes
of acute rejection were treated with pulse doses of methyl-
prednisolone; second episodes, with thymoglobulin.
Delayed graft function was deﬁned as the need for dialysis
within the ﬁrst postoperative week. Renal transplant func-
tion was monitored by serial serum and urine creatinine,
urinary output, and renography. Renal graft failure was
deﬁned as removal of the graft or loss of function requiring
return to dialysis. After transplantation, the urinary output
volumes through the stent and the indwelling bladder cath-
eterwerecollectedseparatelyeachday.Theseurinaryoutput
volumes were only measured in the stented group. A uro-
logical complication was deﬁned as any cause (e.g., urinary
ﬁstula, leakage, ureteral obstruction) requiring a percuta-
neous nephrostomy catheter and/or surgical revision. Uri-
nary tract infections and vesicoureteral reﬂux were not
counted as urological complications. Urinary tract infection
was deﬁned as bacteriuria conﬁrmed by a positive urine
culture. If indicated, a percutaneous nephrostomy catheter
wasinsertedandantegradepyelographywasperformed.The
nephrostomy catheter was left in place to maintain renal
excretoryfunction.Routinely,thenephrostomycatheterwas
changedevery6 weeksatouroutpatientclinic.Iftheurinary
obstruction persisted despite a well-functioning percutane-
ous nephrostomy catheter, an operative reconstruction was
usually performed 3–6 months later.
Statistical analysis
Comparisons of categorical data were performed using the
Chi-square test. Continuous data were compared between
the groups using the Mann–Whitney U-test. Univariate
logistic regression analysis was performed to identify risk
factors for urological complication. The graft survival rates
were calculated by the Kaplan–Meier technique and the
log-rank test. A P value of\0.05 was considered statisti-
cally signiﬁcant. For statistical analyses the SPSS software
package (SPSS 14.0.2, Chicago, IL) was used.
Results
Donorandrecipient characteristicsare presentedinTable 1.
Of the 392 consecutive patients receiving renal transplants,
34 developed a urological complication (8.7%). In the non-
stentedgroup21oftheﬁrst196patients(10.7%)developeda
urological complication, compared to 13 patients of the 196
patients (6.6%) in the stented group P = 0.151 (Table 2).
Two patients in the stented group did not receive a ureter
stent, because of a very small bladder. One of these patients
developed a urological complication. In the stented group, 2
of the 66 recipients of a living donor transplant (3.0%)
developedaurologicalcomplicationcomparedto8ofthe59
recipients (13.6%) in the non-stented group P = 0.030.
Eleven of 130 recipients of a deceased donor transplant
(8.5%) in the stented group developed a urological compli-
cation, compared to 13 of the 137 recipients (9.5%) in the
non-stented group P = 0.769. In the stented group, the 13
urological complications included 10 ureteral strictures
(76.9%) and 3 ureteral leaks. In 8 of these 13 patients, the
urological complication was managed using a temporary
percutaneousnephrostomycatheteronly.Intheremaining5,
surgicalrevision(aneo-ureterocystostomy)wasnecessaryto
correct the urological complication. In the non-stented
group, the 21 urological complications included 15 ureteral
strictures (71.4%) and 6 ureteral leaks. In 15 of these 21
patients, the urological complication was managed using a
temporary percutaneous nephrostomy catheter only. The
remainingsixpatientsunderwentasurgicalrevision.Inboth
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operation, and no reoperations were necessary. In both
groups, the majority of complications occurred within the
ﬁrst postoperative month (Fig. 1). After placement, the
percutaneous nephrostomy catheter remained in situ for
varying lengths of time. The mean (±SD) percutaneous
nephrostomycathetertime(days)was146 ± 40(range:12–
411 days) in the stented group and 155 ± 45 days (range:
17–440 days) in the non-stented group. Urinary tract infec-
tion in the stented group occurred in 41 patients (20.9%),
compared to 45 patients (22.9%) in the non-stented group
P = 0.689. The surgical outcomes are shown in Table 3.
During the ﬁrst 5 days, the urinary output volumes via
the stent were signiﬁcantly lower in the urological com-
plication group than in the non-urological complication
group (P = 0.026) (Fig. 1). During this period no differ-
ences in urinary output volume through the indwelling
bladder catheter between these groups were found
(P = 0.278).
The 1-month survival in the two groups was identical at
93% and that at 1 year the survival rate was again identical
at 89%.
Discussion
A routine short-duration stenting protocol of 5 days
resulted in a urological complication rate of 6.6% for all
renal transplants. There was a urological complication rate
of 3.0% in transplants from living donors and 8.5% from
deceased donors. Compared with our non-stented uretero-
neocystostomy group, the overall urological complication
rate at our center was reduced from 10.7 to 6.6%. In the
living donor group, the urological complication rate was
reduced from 13.6 to 3.0%. In the deceased donor group it
was reduced from 9.5 to 8.5%.
Classically, the two major etiological factors for uro-
logical complications after renal transplantation are surgi-
cal–technical factors and distal transplant ureteral
ischemia. Surgical–technical factors include poor harvest-
ing and ureterocystostomy techniques. Measures including
the preservation of the periureteral vessels and fat, avoid-
ance of large incisions in the bladder, the reduction of
ureteral length, avoidance of external ureteral compression
by the vas deferens, and creating a watertight urinary
anastomosis, all decrease the incidence of urological
complications [5]. The most frequent causes of urinary
leakage are necrosis and suture failure [6], whereas ureteral
strictures might result from intraluminary factors, such as
calculi, blood clots, or extraluminary factors such as
compression of blood and lymphatic ﬂuid [5].
A ureterocystostomy protocol in a selected group of
transplant recipients would be an option to reduce the high
NNT for routine stenting. However, to date no useful
preoperative and/or perioperative factors have been iden-
tiﬁed that would serve to predict postoperative urological
Table 1 Demographics of donors and recipients
Variable No stent
(n = 196)
Stent
(n = 196)
P value
Donor
Male 80 (41%) 80 (41%) 0.452
Age
\18 years 14 (7%) 10 (5%) 0.188
18–40 years 49 (25%) 65 (33%) 0.145
40–65 years 120 (61%) 110 (56%) 0.537
[65 years 13 (7%) 11 (6%) 0.836
Left kidney 81 (41%) 113 (58%) 0.005
Living related transplantation 59 (30%) 66 (34%) 0.448
Recipient
Male 121 (62%) 101 (52%) 0.047
Age
\18 years 13 (6%) 13 (7%) 0.695
18–40 years 54 (28%) 50 (25%) 0.647
40–65 years 108 (55%) 115 (59%) 0.475
[65 years 19 (9%) 18 (9%) 0.863
First transplantation 164 (84%) 163 (83%) 0.892
Second transplantation 29 (15%) 24 (12%) 0.460
Third and fourth transplantations 3 (1%) 9 (5%) 0.079
Table 2 Urological complications and treatment
No stent (n = 196) Stent (n = 196) P value
Urological complications
Living donor 8/59 (13.6)% 2/66 (3.0)% 0.030
Deceased donor 13/137 (9.5%) 11/130 (8.5%) 0.769
Surgical revision 6/21 (29)% 5/13 (39)% 0.760
Fig. 1 Time interval between the operation and occurrence of the
urological complication
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selective stenting protocol [7, 8]. In addition, in a retro-
spective analysis, Georgiev et al. [8] recently demonstrated
that routine stenting of the ureterocystostomy is superior to
stenting on demand.
Six of the seven randomized trials that compared stenting
with no stenting, used a double-J stent with a treatment
duration of between 2 weeks and 3 months [9–14]. The
seventh study used an external 8 Fr straight stent for
7–10 days [15]. Side effects and complications of stents,
especially the double-J stent, include patient discomfort and
irritated bladder symptoms, bacteriuria with or without
clinical signs of infection, urosepsis, hematuria, ﬂank and
loin pain on the same side as the stent, dislocation of the
stent, fragmentation, and calciﬁcation [16]. The presence of
the double-J stent for a long period increases the risk of
urinary tract infection [4]. An additional disadvantage of a
double-J stent is the need for a cystoscopy and anesthesia
for stent removal. Urological complication rates of double-J
stents vary between 0 and 4% [2]. Junjie et al. [17] exam-
ined the duration of stent placement and reported a lower
urological complication rate in the group whohad a stent for
5–7 days (4.3%) compared with 3–4 weeks (7.7%).
Our protocol involved the use of an externally draining 8
Fr catheter for 5 days. An advantage of using this type of
stent is that it avoids the complications associated with the
double-J stent and the additional cystoscopy required for
stent removal. Our urological complication rate from using
a double-J stent in the living donor transplantation group is
comparable with that found in the literature [1, 2]. Thus,
our protocol has the additional advantage of eliminating the
extra intervention necessary for stent removal with a
comparable complication rate in living donor transplant
recipients. However, the 5-day period of stenting in the
patients with transplants from deceased donors resulted in a
rather high urological complication rate of 8.5%, if com-
pared with a complication rate of less than 2–3% as
reported from several randomized trials [2].
The use of a stent resulted in a signiﬁcantly increased
risk of a urinary tract infection when compared with the
non-stented ureterocystostomy (relative risk 1.49, 95% CI:
1.04–2.15; P = 0.03) [2]. Our rate was 20.9%, whereas the
reported urinary tract infection prevalence was 25.8% [2].
Indwelling ureteral stents are often associated with the
development of recurrent urinary tract infection. Possibly
our urinary tract infection rate is lower because of the short
duration of stent placement.
The main limitation of the present study is the use of a
historical control group instead of a randomized contem-
poraneous control group.
We conclude that there was signiﬁcant beneﬁt of
stenting in the living donor group. A strong advantage of
our short-duration external stenting protocol was not seen
in the deceased group, whereas there was a suggestion of
trend toward better outcomes with stenting in the patients
overall. For future research large randomized controlled
studies would be useful, especially in deceased donor
kidney transplants.
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